


Australian Experimental Liver Cancer Research Network

Liver Cancer Forum 2022



3rd & 4th June 2022

Mary Emelia Room
The University of Queensland
Herston, Brisbane

Presented by the
Gallipoli Medical Research Foundation
Liver Cancer Unit

Gold Sponsor

AstraZeneca 

Silver Sponsor



Day One - Friday 3 June, 2022

Forum Opening	
9:30am - 10:00am	Arrival and registration
10:00am - 10:05am	Welcome Address Prof. Darrell Crawford and Prof. Geoff McCaughan
10:05am - 10:15am	Welcome and Introduction to The University of Queensland Medical School Prof. John Pearn
Session One	
Check Point Inhibitors and Hepatocellular Cancer	
10:15am - 10:45am	Immunotherapy and the NAFLD immune microenvironment A/Prof. Amany Zekry
10:45am - 11:00am	Prognostic role of immune checkpoint regulators in Cholangiocarcinoma: A pilot study Dr. Aparna Jayachandran
11:00am - 11:15am	YTHDF2 transcriptionally programs effector T cells in tumor immunity Dr. Jiajie Hou
11:15am - 11:30am	Novel miRNA-based drug CD5-2 reduces liver tumour growth in diethylnitrosamine (DEN)-treated mice by normalising tumour vasculature and altering immune infiltrate Dr. Ken Liu
11:30am - 12:00pm	Keynote Address Dr. Zhian Chen
12:00pm - 12:15pm	AstraZeneca Presentation Lakmali Atapattu
12:15 - 12:30pm	General Discussion
12:30pm - 1:15pm	
LUNCH	
Session Two	
Drug Resistance	
1:15pm - 1:45pm	Biomarkers for tackling immunotherapy resistance Prof. Sudha Rao
1:45pm - 2:00pm	ROS mediated hepatic stellate cell activation via PI3K pathway during chemotherapy in liver cancer Qi Ruan
2:00pm - 2:15pm	Therapeutic potential of macrophage colony-stimulating factor (CSF1) in chronic liver disease Dr. Sahar Keshvari
2:15pm - 2:30pm	Matrix optimisation of precision-bioprinted hepatocellular carcinoma organoids for drug screening Dr. Gayatri Shirolkar
2:30pm - 2:45pm	Impact of vessels that encapsulate tumour clusters vascular pattern on hepatocellular carcinoma recurrence following liver transplantation - a 10-year Australian study - Dr. Ken Liu
2:45pm - 3:00pm	Elsai Presentation Chunyan Ma
3:00pm - 3:15pm	General Discussion
3:15pm - 3:45pm	
AFTERNOON TEA	
Session Three	
HCC - Molecular Phenotyping for HCC	
3:45pm - 4:15pm	Advances in molecular phenotyping Prof. Nina Tirnitz-Parker
4:15pm - 4:30pm	c-Myc driven dedifferentiation and growth require GTP biosynthesis Dr. Andy Cox
4:30pm - 4:45pm	The Characterisation of Tumour Self-Seeded Cells in Liver Cancer Haotian Yang
4:45pm - 5:00pm	The HGF/c-MET signalling pathway is a key regulator of liver progenitor cell function and maintenance of epithelial cell characteristics Sara Pasic
5:00pm - 5:15pm	A functional MSC-derived liver on a chip for modelling liver diseases Anastasia Brooks
5:15pm - 5:25pm	Abacus Presentation Chris Pickup
5:25pm - 5:40pm	Discussion and wrap-up
5:40pm - 7:00pm	
DRINKS & CANAPES - PRESENTED BY 	

Day Two - Saturday 4 June, 2022

Opening	
8:30am - 9:00am	Arrival and registration
Session Four	
<i>Microbiome, MAFLD and Liver Cancer</i>	
9:00am - 9:30am	The role of the microbiome in HCC Prof. Emad El-Omar
9:30am - 9:45am	Interrogating the tumour microenvironment in hepatocellular carcinoma Dr. Felix Marsh-Wakefield
9:45am - 10:00am	Effect of Gut influence on the immune environment in pre-clinical HCC Dr Sj Shen
10:00am - 10:15am	Salivary biomarkers of liver fibrosis: Evidence for a potential role in diagnosis Lucas Trevisan Franca de Lima
10:15am - 10:30am	MORNING TEA
10:30am - 11:00am	Mechanisms driving NASH and liver cancer Prof. Tony Tiganis
11:00am - 11:15am	A novel mediator of Cholangiocarcinoma that has potential as a Diagnostic and Treatment Target Dr. Lash Mickramasuriya
11:15am - 11:30am	Loss of primary cilia and PTEN in biliary epithelial cells contributes to intrahepatic cholangiocarcinoma formation in TAA-treated adult mice Dr. Jinbiao Chen / Prof. Geoff McCaughan
11:30am - 11:45am	General discussion and wrap-up
PROGRAM CLOSE	

THANK YOU TO OUR SPONSORS

Gold Sponsor



Silver Sponsor



Networking Sponsor

